F.P.S and M.S. have equally contributed to this study and should be treated as first co-authors
High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer
Article first published online: 12 APR 2013
© 2013 BJU International
Volume 111, Issue 5, pages 836–842, May 2013
How to Cite
Smit, F. P., Salagierski, M., Jannink, S. and Schalken, J. A. (2013), High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer. BJU International, 111: 836–842. doi: 10.1111/bju.12119
- Issue published online: 12 APR 2013
- Article first published online: 12 APR 2013
- European Association of Urology (EAU). Grant Number: S-02-2008
- prostate cancer;
- TMPRSS2-ERG fusions
- To assess whether oestrogen-regulated gene (ERG) expression analysis using GeneChip arrays can predict transmembrane protease, serine 2 (TMPRSS2)-ERG fusion. The expression level of the TMPRSS2-ERG gene was studied in various histological grades of prostate cancer and castration-resistant prostate cancer (CPRC).
Patients and methods
- GeneChip Affymetrix exon 1.0 ST arrays were used for expression profiling of ERG, erythroblast transformation-specific (ETS) variant gene 1 (ETV1), ETV4 and ETV5 genes in 67 prostate cancer tissue specimens.
- Real-time quantitative polymerase chain reaction analysis and in some cases DNA sequencing was used to validate the presence and the expression levels of TMPRSS2-ERG gene fusions.
- In our series of patients with prostate cancer over expression of the ERG gene predicted the presence of TMPRSS2-ERG rearrangements in almost all cases.
- ETS expression by itself outmatched the diagnostic performance of the ERG exons ratioing allowing equal detection of the less frequent ETS gene fusion transcripts.
- The gene fusions were expressed at significantly lower levels in CPRC but occurred more frequently than in primary prostate cancer.
- ERG expression analysis using GeneChip arrays appears to be an excellent diagnostic tool for identifying gene rearrangements.
- In coming years, measuring expression of the ETS gene family by itself might become a clinically relevant surrogate test to identify patients with fusion-positive prostate cancer.
- The variation of gene fusion expression levels, particularly in CPRC, needs to be taken into account when using quantitative molecular diagnosis of prostate cancer.